FDA scolds drugmaker over promotion that touts ‘misleading’ comparison with generics

Taking stock of the drug industry, from the lab to the medicine chest

March 4, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FDA scolds drugmaker over promotion that touts 'misleading' comparison with generics The agency said an Edenbridge Pharmaceuticals' promotional panel falsely maintained there was greater patient adherence to its drug compared with generics. By Ed Silverman STAT+ | Marty Makary, Trump nominee to lead FDA, pledges to avoid conflicts if confirmed The pancreatic surgeon said he would step down from advisory roles and sell certain assets if confirmed as FDA commissioner. By Lizzy Lawrence Opinion: Health plans need to take accountability for a broken system I left health care organizations because the system was broken. Now I want to fix it. By Michael Waterbury Photo illustration: STAT; Photo: Stanford Health Policy STAT+ | 'Wrong,' 'misleading,' and 'reasonable': How Jay Bhattacharya became, for some, the least bad option to run NIH Trump NIH nominee mixes Stanford credentials and Covid contrarianism. Some scientists have reservations, but say another appointee would likely be worse By Eric Boodman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser